Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy for Newly Diagnosed Medulloblastoma (SJMB12)
NCT01878617Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2013
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of vismodegib, pemetrexed, gemcitabine in medulloblastoma, sponsored by St. Jude Children's Research Hospital. Started Jun 2013; status: active, not recruiting.
02
Drugs
vismodegibpemetrexedgemcitabine
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT01878617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01878617.